Copeland Capital Management, LLC Gilead Sciences, Inc. Transaction History

Copeland Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 27, 2021	SELL	$56.65 - $64.55 $1,529 - $1,742	-27 Closed	0 $0
Q3 2020 Jan 18, 2022	BUY	$62.1 - $78.08 $1,676 - $2,108	27 New	27 $2,000
Q3 2020 Oct 22, 2020	SELL	$62.1 - $78.08 $1,676 - $2,108	-27 Closed	0 $0
Q2 2020 Jan 18, 2022	BUY	$72.34 - $84.0 $1,953 - $2,268	27 New	27 $2,000
Q3 2019 Nov 06, 2019	SELL	$62.51 - $69.0 $1,312 - $1,449	-21 Closed	0 $0
Q2 2019 Jan 18, 2022	BUY	$61.87 - $69.38 $1,299 - $1,456	21 New	21 $1,000
Q2 2019 Jul 19, 2019	SELL	$61.87 - $69.38 $1,299 - $1,456	-21 Closed	0 $0
Q1 2019 Jan 18, 2022	BUY	$62.53 - $70.05 $1,313 - $1,471	21 New	21 $1,000
Q1 2019 Apr 24, 2019	SELL	$62.53 - $70.05 $1,313 - $1,471	-21 Closed	0 $0
Q4 2018 Jan 18, 2022	BUY	$60.54 - $79.0 $1,271 - $1,659	21 New	21 $1,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Copeland Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Copeland Capital Management, LLC with notifications on news.